Considering that the PSMA expression of tumor-associated neovasculature is low in most preclinical RCC models, we developed a human PSMA-transduced murine RCC cell, PSMA+ RENCA, as a model for a proof-of-concept preclinical therapy study. The gene discussed is FOLH1; the disease is neoplasm.